Orgenesis (ORGS) News Today → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free ORGS Stock Alerts $0.57 -0.04 (-6.45%) (As of 04:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 17, 2024 | investing.comOrgenesis secures $2.3 million investment and strategic partnershipApril 17, 2024 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Year End Business UpdateApril 15, 2024 | globenewswire.comOrgenesis Provides Year End Business UpdateApril 11, 2024 | investing.comGermfree partners with Orgenesis to enhance CGT productionApril 10, 2024 | globenewswire.comGermfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityMarch 18, 2024 | globenewswire.comVered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceMarch 13, 2024 | globenewswire.comOrgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesMarch 4, 2024 | globenewswire.comOrgenesis Inc. Announces $2.3 Million Private PlacementFebruary 29, 2024 | globenewswire.comOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingFebruary 23, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS)February 22, 2024 | morningstar.comOrgenesis Inc ORGSJanuary 31, 2024 | msn.comEXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To ClinicJanuary 31, 2024 | finance.yahoo.comOrgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicJanuary 8, 2024 | finance.yahoo.comOrgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo FinanceNovember 22, 2023 | finance.yahoo.comAnalysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven SoonNovember 15, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comOrgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNovember 13, 2023 | finance.yahoo.comOrgenesis Provides Business Update for the Third Quarter of 2023November 8, 2023 | finance.yahoo.comOrgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNovember 5, 2023 | forbes.com6 Secrets Of Organizations That Successfully Adapt To ChangeNovember 2, 2023 | finance.yahoo.comOrgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingOctober 31, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Withdrawal of Proposed Public OfferingOctober 30, 2023 | finance.yahoo.comOrgenesis Announces Proposed Underwritten Public OfferingSeptember 21, 2023 | stockhouse.comCGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesSeptember 21, 2023 | finance.yahoo.comCGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesAugust 28, 2023 | finance.yahoo.comOrgenesis Inc (ORGS): A Deep Dive into Its Performance PotentialAugust 28, 2023 | finance.yahoo.comIs Orgenesis (ORGS) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapAugust 24, 2023 | finance.yahoo.comOrgenesis (ORGS): A Value Trap in Disguise?August 13, 2023 | abcnews.go.comHow to help Maui fire victims from afar: Organizations and efforts underwayAugust 11, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Provides Business Update for Second Quarter of 2023August 11, 2023 | finance.yahoo.comOrgenesis Provides Business Update for Second Quarter of 2023August 10, 2023 | finance.yahoo.comOrgenesis Schedules Second Quarter 2023 Business Update Conference CallJuly 13, 2023 | finanznachrichten.deOrgenesis Inc.: Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial OfficerJuly 13, 2023 | marketwatch.comOrgenesis Names Maltz Finance Chief as Reithinger Resigns >ORGSJuly 13, 2023 | finance.yahoo.comOrgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial OfficerJuly 11, 2023 | finance.yahoo.comOrgenesis Announces Name Change of Morgenesis Business Unit to OctomeraJune 15, 2023 | finance.yahoo.comOrgenesis Inc. (NASDAQ:ORGS) On The Verge Of Breaking EvenJune 7, 2023 | finance.yahoo.comOrgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout CaliforniaMay 30, 2023 | finance.yahoo.comClaudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of OrgenesisMay 22, 2023 | benzinga.comOrgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master's ProgramMay 22, 2023 | finance.yahoo.comOrgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master’s ProgramMay 19, 2023 | finance.yahoo.comOrgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023May 18, 2023 | finance.yahoo.comOrgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus VectorsMay 10, 2023 | finance.yahoo.comOrgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare StrategyMay 10, 2023 | finance.yahoo.comOrgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service SubsidiaryApril 26, 2023 | forbes.comThe Secret To Sustainability For Non-profit OrganizationsApril 25, 2023 | finance.yahoo.comOrgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy ManufacturingApril 22, 2023 | venturebeat.comCrowdStrike turns to managed XDR to help orgs navigate the cyber skills gapApril 19, 2023 | finance.yahoo.comOrgenesis Inc.'s (NASDAQ:ORGS) Share Price Is Matching Sentiment Around Its Revenues Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. ORGS Media Mentions By Week ORGS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORGS News Sentiment▼1.430.55▲Average Medical News Sentiment ORGS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORGS Articles This Week▼20▲ORGS Articles Average Week Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aptorum Group News NeuroSense Therapeutics News NeuroBo Pharmaceuticals News Indaptus Therapeutics News Vincerx Pharma News Minerva Neurosciences News VBI Vaccines News Flora Growth News Galecto News Aytu BioPharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORGS) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.